• Je něco špatně v tomto záznamu ?

Necrosis-like cell death modes in heart failure: the influence of aetiology and the effects of RIP3 inhibition

I. Jarabicová, C. Horváth, J. Hrdlička, A. Boroš, V. Olejníčková, E. Zábrodská, SŠ. Hubáčková, HM. Šutovská, Ľ. Molčan, L. Kopkan, M. Chudý, B. Kura, B. Kaločayová, E. Goncalvesová, J. Neckář, M. Zeman, F. Kolář, A. Adameová

. 2025 ; 120 (2) : 373-392. [pub] 20250315

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25016251

Grantová podpora
APVV-20-0242 Agentúra na Podporu Výskumu a Vývoja
APPV-15-0607 Agentúra na Podporu Výskumu a Vývoja
NU21J-02-00039 Agentura Pro Zdravotnický Výzkum České Republiky
NU22-01-00096 Agentura Pro Zdravotnický Výzkum České Republiky
LX22NPO5104 National Institute for Research of Metabolic and Cardiovascular Diseases, Programme EXCELES
09I03-03-V04-00231 European Union - Next generation EU
IN 00023001 Ministerstvo Zdravotnictví Ceské Republiky

Since cell dying in heart failure (HF) may vary based on the aetiology, we examined the main forms of regulated necrosis, such as necroptosis and pyroptosis, in the hearts damaged due to myocardial infarction (MI) or pressure overload. We also investigated the effects of a drug inhibiting RIP3, a proposed convergent point for both these necrosis-like cell death modes. In rat hearts, left ventricular function, remodelling, pro-cell death, and pro-inflammatory events were investigated, and the pharmacodynamic action of RIP3 inhibitor (GSK'872) was assessed. Regardless of the HF aetiology, the heart cells were dying due to necroptosis, albeit the upstream signals may be different. Pyroptosis was observed only in post-MI HF. The dysregulated miRNAs in post-MI hearts were accompanied by higher levels of a predicted target, HMGB1, its receptors (TLRs), as well as the exacerbation of inflammation likely originating from macrophages. The RIP3 inhibitor suppressed necroptosis, unlike pyroptosis, normalised the dysregulated miRNAs and tended to decrease collagen content and affect macrophage infiltration without affecting cardiac function or structure. The drug also mitigated the local heart inflammation and normalised the higher circulating HMGB1 in rats with post-MI HF. Elevated serum levels of HMGB1 were also detected in HF patients and positively correlated with C-reactive protein, highlighting pro-inflammatory axis. In conclusion, in MI-, but not pressure overload-induced HF, both necroptosis and pyroptosis operate and might underlie HF pathogenesis. The RIP3-targeting pharmacological intervention might protect the heart by preventing pro-death and pro-inflammatory mechanisms, however, additional strategies targeting multiple pro-death pathways may exhibit greater cardioprotection.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25016251
003      
CZ-PrNML
005      
20250731091635.0
007      
ta
008      
250708s2025 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00395-025-01101-4 $2 doi
035    __
$a (PubMed)40088261
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Jarabicová, Izabela $u Faculty of Pharmacy, Department of Pharmacology and Toxicology, Comenius University, Odbojárov 10, 832 32, Bratislava, Slovak Republic
245    10
$a Necrosis-like cell death modes in heart failure: the influence of aetiology and the effects of RIP3 inhibition / $c I. Jarabicová, C. Horváth, J. Hrdlička, A. Boroš, V. Olejníčková, E. Zábrodská, SŠ. Hubáčková, HM. Šutovská, Ľ. Molčan, L. Kopkan, M. Chudý, B. Kura, B. Kaločayová, E. Goncalvesová, J. Neckář, M. Zeman, F. Kolář, A. Adameová
520    9_
$a Since cell dying in heart failure (HF) may vary based on the aetiology, we examined the main forms of regulated necrosis, such as necroptosis and pyroptosis, in the hearts damaged due to myocardial infarction (MI) or pressure overload. We also investigated the effects of a drug inhibiting RIP3, a proposed convergent point for both these necrosis-like cell death modes. In rat hearts, left ventricular function, remodelling, pro-cell death, and pro-inflammatory events were investigated, and the pharmacodynamic action of RIP3 inhibitor (GSK'872) was assessed. Regardless of the HF aetiology, the heart cells were dying due to necroptosis, albeit the upstream signals may be different. Pyroptosis was observed only in post-MI HF. The dysregulated miRNAs in post-MI hearts were accompanied by higher levels of a predicted target, HMGB1, its receptors (TLRs), as well as the exacerbation of inflammation likely originating from macrophages. The RIP3 inhibitor suppressed necroptosis, unlike pyroptosis, normalised the dysregulated miRNAs and tended to decrease collagen content and affect macrophage infiltration without affecting cardiac function or structure. The drug also mitigated the local heart inflammation and normalised the higher circulating HMGB1 in rats with post-MI HF. Elevated serum levels of HMGB1 were also detected in HF patients and positively correlated with C-reactive protein, highlighting pro-inflammatory axis. In conclusion, in MI-, but not pressure overload-induced HF, both necroptosis and pyroptosis operate and might underlie HF pathogenesis. The RIP3-targeting pharmacological intervention might protect the heart by preventing pro-death and pro-inflammatory mechanisms, however, additional strategies targeting multiple pro-death pathways may exhibit greater cardioprotection.
650    _2
$a zvířata $7 D000818
650    12
$a serin-threoninkinasy interagující s receptory $x antagonisté a inhibitory $x metabolismus $7 D053422
650    12
$a srdeční selhání $x patologie $x enzymologie $x patofyziologie $x farmakoterapie $x etiologie $x genetika $7 D006333
650    12
$a nekroptóza $x účinky léků $7 D000079302
650    _2
$a mužské pohlaví $7 D008297
650    12
$a pyroptóza $x účinky léků $7 D000069292
650    _2
$a modely nemocí na zvířatech $7 D004195
650    12
$a kardiomyocyty $x účinky léků $x patologie $x enzymologie $7 D032383
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a nekróza $7 D009336
650    _2
$a funkce levé komory srdeční $x účinky léků $7 D016277
650    _2
$a mikro RNA $x metabolismus $x genetika $7 D035683
650    _2
$a remodelace komor $x účinky léků $7 D020257
650    _2
$a potkani Sprague-Dawley $7 D017207
650    12
$a inhibitory proteinkinas $x farmakologie $7 D047428
655    _2
$a časopisecké články $7 D016428
700    1_
$a Horváth, Csaba $u Faculty of Pharmacy, Department of Pharmacology and Toxicology, Comenius University, Odbojárov 10, 832 32, Bratislava, Slovak Republic
700    1_
$a Hrdlička, Jaroslav $u Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Boroš, Almos $u Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Olejníčková, Veronika $u Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic $u First Faculty of Medicine, Institute of Anatomy, Charles University, Prague, Czech Republic
700    1_
$a Zábrodská, Eva $u First Faculty of Medicine, Institute of Anatomy, Charles University, Prague, Czech Republic
700    1_
$a Hubáčková, Soňa Štemberková $u Institute for Clinical and Experimental Medicine, Prague, Czech Republic $u Institute of Biotechnology, Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Šutovská, Hana Mauer $u Faculty of Natural Sciences, Department of Animal Physiology and Ethology, Comenius University, Bratislava, Slovak Republic
700    1_
$a Molčan, Ľuboš $u Faculty of Natural Sciences, Department of Animal Physiology and Ethology, Comenius University, Bratislava, Slovak Republic
700    1_
$a Kopkan, Libor $u Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Chudý, Martin $u Faculty of Medicine, Department of Cardiology, Comenius University and National Cardiovascular Institute, Bratislava, Slovak Republic
700    1_
$a Kura, Branislav $u Centre of Experimental Medicine, Institute for Heart Research, Slovak Academy of Sciences, Bratislava, Slovak Republic
700    1_
$a Kaločayová, Barbora $u Centre of Experimental Medicine, Institute for Heart Research, Slovak Academy of Sciences, Bratislava, Slovak Republic
700    1_
$a Goncalvesová, Eva $u Faculty of Medicine, Department of Cardiology, Comenius University and National Cardiovascular Institute, Bratislava, Slovak Republic
700    1_
$a Neckář, Jan $u Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Zeman, Michal $u Faculty of Natural Sciences, Department of Animal Physiology and Ethology, Comenius University, Bratislava, Slovak Republic
700    1_
$a Kolář, František $u Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Adameová, Adriana $u Faculty of Pharmacy, Department of Pharmacology and Toxicology, Comenius University, Odbojárov 10, 832 32, Bratislava, Slovak Republic. adameova@fpharm.uniba.sk $u Centre of Experimental Medicine, Institute for Heart Research, Slovak Academy of Sciences, Bratislava, Slovak Republic. adameova@fpharm.uniba.sk
773    0_
$w MED00009296 $t Basic research in cardiology $x 1435-1803 $g Roč. 120, č. 2 (2025), s. 373-392
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40088261 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731091630 $b ABA008
999    __
$a ok $b bmc $g 2366828 $s 1253376
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 120 $c 2 $d 373-392 $e 20250315 $i 1435-1803 $m Basic research in cardiology $n Basic Res Cardiol $x MED00009296
GRA    __
$a APVV-20-0242 $p Agentúra na Podporu Výskumu a Vývoja
GRA    __
$a APPV-15-0607 $p Agentúra na Podporu Výskumu a Vývoja
GRA    __
$a NU21J-02-00039 $p Agentura Pro Zdravotnický Výzkum České Republiky
GRA    __
$a NU22-01-00096 $p Agentura Pro Zdravotnický Výzkum České Republiky
GRA    __
$a LX22NPO5104 $p National Institute for Research of Metabolic and Cardiovascular Diseases, Programme EXCELES
GRA    __
$a 09I03-03-V04-00231 $p European Union - Next generation EU
GRA    __
$a IN 00023001 $p Ministerstvo Zdravotnictví Ceské Republiky
LZP    __
$a Pubmed-20250708
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace